Graham Peter Lidgard Sells 38,311 Shares of EXACT Sciences Co. (EXAS) Stock

EXACT Sciences Co. (NASDAQ:EXAS) insider Graham Peter Lidgard sold 38,311 shares of the business’s stock in a transaction on Wednesday, November 7th. The stock was sold at an average price of $75.01, for a total transaction of $2,873,708.11. Following the transaction, the insider now owns 29,398 shares in the company, valued at $2,205,143.98. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Graham Peter Lidgard also recently made the following trade(s):

  • On Monday, November 5th, Graham Peter Lidgard sold 37,613 shares of EXACT Sciences stock. The stock was sold at an average price of $75.01, for a total transaction of $2,821,351.13.
  • On Thursday, November 1st, Graham Peter Lidgard sold 79,673 shares of EXACT Sciences stock. The stock was sold at an average price of $71.73, for a total transaction of $5,714,944.29.
  • On Monday, October 8th, Graham Peter Lidgard sold 58,000 shares of EXACT Sciences stock. The stock was sold at an average price of $69.36, for a total transaction of $4,022,880.00.

EXAS stock traded up $1.26 during midday trading on Wednesday, reaching $75.48. 1,456,400 shares of the company were exchanged, compared to its average volume of 2,469,468. The company has a debt-to-equity ratio of 0.94, a current ratio of 12.08 and a quick ratio of 11.72. EXACT Sciences Co. has a one year low of $37.36 and a one year high of $81.22. The stock has a market cap of $9.12 billion, a price-to-earnings ratio of -76.24 and a beta of 1.21.

EXACT Sciences (NASDAQ:EXAS) last released its quarterly earnings data on Tuesday, October 30th. The medical research company reported ($0.37) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.42) by $0.05. EXACT Sciences had a negative net margin of 35.83% and a negative return on equity of 20.18%. The firm had revenue of $118.29 million during the quarter, compared to analysts’ expectations of $109.33 million. During the same period in the previous year, the business posted ($0.23) earnings per share. The company’s revenue for the quarter was up 63.0% compared to the same quarter last year. Research analysts anticipate that EXACT Sciences Co. will post -1.53 EPS for the current fiscal year.

EXAS has been the topic of a number of recent analyst reports. Leerink Swann restated an “outperform” rating and set a $76.00 target price (up from $67.00) on shares of EXACT Sciences in a report on Wednesday, July 18th. Bank of America lifted their price objective on shares of EXACT Sciences from $67.00 to $75.00 and gave the stock a “buy” rating in a research report on Monday, July 23rd. BidaskClub cut shares of EXACT Sciences from a “buy” rating to a “hold” rating in a research report on Thursday, July 26th. Craig Hallum reduced their price objective on shares of EXACT Sciences from $60.00 to $54.00 and set a “buy” rating for the company in a research report on Thursday, August 2nd. Finally, Jefferies Financial Group reduced their price objective on shares of EXACT Sciences from $60.00 to $57.00 and set a “buy” rating for the company in a research report on Thursday, August 2nd. Four research analysts have rated the stock with a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the stock. EXACT Sciences currently has an average rating of “Buy” and a consensus target price of $84.08.

A number of hedge funds have recently added to or reduced their stakes in EXAS. Asymmetry Capital Management L.P. boosted its position in shares of EXACT Sciences by 229.2% in the second quarter. Asymmetry Capital Management L.P. now owns 84,937 shares of the medical research company’s stock valued at $5,078,000 after acquiring an additional 59,134 shares during the period. Private Wealth Partners LLC boosted its position in shares of EXACT Sciences by 16.7% in the second quarter. Private Wealth Partners LLC now owns 70,000 shares of the medical research company’s stock valued at $4,185,000 after acquiring an additional 10,000 shares during the period. Swiss National Bank boosted its position in shares of EXACT Sciences by 1.4% in the second quarter. Swiss National Bank now owns 210,619 shares of the medical research company’s stock valued at $12,593,000 after acquiring an additional 3,000 shares during the period. Sit Investment Associates Inc. boosted its position in shares of EXACT Sciences by 24.3% in the second quarter. Sit Investment Associates Inc. now owns 33,300 shares of the medical research company’s stock valued at $1,991,000 after acquiring an additional 6,500 shares during the period. Finally, Legal & General Group Plc boosted its position in shares of EXACT Sciences by 10.4% in the second quarter. Legal & General Group Plc now owns 56,154 shares of the medical research company’s stock valued at $3,358,000 after acquiring an additional 5,312 shares during the period. 87.06% of the stock is owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION NOTICE: “Graham Peter Lidgard Sells 38,311 Shares of EXACT Sciences Co. (EXAS) Stock” was originally reported by WKRB News and is the sole property of of WKRB News. If you are reading this news story on another publication, it was stolen and reposted in violation of United States & international copyright laws. The original version of this news story can be accessed at https://www.wkrb13.com/2018/11/08/graham-peter-lidgard-sells-38311-shares-of-exact-sciences-co-exas-stock.html.

EXACT Sciences Company Profile

Exact Sciences Corporation, a molecular diagnostics company, focuses on developing products for the early detection and prevention of various cancers in the United States. The company offers Cologuard, a non-invasive stool-based DNA screening test for the early detection of colorectal cancer and pre-cancer.

Further Reading: What is the NASDAQ Stock Market?

Insider Buying and Selling by Quarter for EXACT Sciences (NASDAQ:EXAS)

Receive News & Ratings for EXACT Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for EXACT Sciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply